A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT06150664
This study is recruiting at 9 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non Small Cell Lung Cancer
- Triple Negative Breast Cancer
- Hodgkin Lymphoma
- Head and Neck Squamous Cell Carcinoma
- Malignant Melanoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Compass Therapeutics
- Last updated on ClinicalTrials.gov
- July 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 2
- Florida Cancer Specialists - Lake Nona · Orlando, FL
- Florida Cancer Specialists - Sarasota · Sarasota, FL
Georgia · 1
- University Cancer & Blood Center · Athens, GA
Indiana · 1
- Fort Wayne Medical Oncology and Hematology · Fort Wayne, IN
Massachusetts · 2
- Beth Israel Deaconess Medical Center · Boston, MA
- Dana-Farber Cancer Institute · Boston, MA
New York · 1
- Roswell Park Cancer Institute · Buffalo, NY
Tennessee · 1
- Tennessee Oncology · Nashville, TN
Washington · 1
- Summit Cancer Center · Spokane, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.